Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor–Positive, ERBB2-Negative Advanced Breast Cancer

帕博西利布 富维斯特朗 来曲唑 医学 肿瘤科 乳腺癌 内科学 阿那曲唑 抗雌激素 临床终点 转移性乳腺癌 人口 癌症 妇科 随机对照试验 三苯氧胺 环境卫生
作者
Antonio Llombart‐Cussac,José Manuel Pérez-García,Meritxell Bellet,Florence Dalenc,Miguel Gil‐Gil,Manuel Ruíz‐Borrego,Joaquín Gavilá,Miguel Sampayo-Cordero,Elena Aguirre,Thomas Powles,Frederik Marmé,Serena Di Cosimo,Joseph Gligorov,Andreas Schneeweiß,Joan Albanell,Pilar Zamora,Duncan Wheatley,Eduardo Martínez-De Dueñas,Kepa Amillano,Andrea Malfettone,Javier Cortés,Antonio Antón,Vladimir Moiseyenko,Paul Cottu,Gemma Viñas,Thierry Petit,Petra Tesařová,Vladimir Vladimirov,Joseph Banuelos,Marco Colleoni,Gianfilippo Bertelli,Purificación Martínez,R. Andrés,Tatiana Barannikova,Sònia Servitja,Jacques Médioni,Saverio Cinieri,Juan Bayo,Santiago González,Bohuslav Melichar,Vicente Caranyana,Francesco Atzori,Mark Beresford,Steven T. F. Chan,Maria Luque-Cabal,Juan de la Haba-Rodríguez,Joachim Bischoff,Guzel Mukhametsina,Marina Elena Cazzaniga,Daniele Generali,Andrew Wardley,Laura Cortesi,Luigi Cavanna,Mario Airoldi
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:7 (12): 1791-1791 被引量:65
标识
DOI:10.1001/jamaoncol.2021.4301
摘要

The cyclin-dependent kinase 4 and 6 inhibitor palbociclib in combination with letrozole has become a standard first-line treatment for patients with endocrine-sensitive, hormone receptor-positive, ERBB2-negative advanced breast cancer. Meanwhile, the antiestrogen fulvestrant was shown to be superior to anastrozole in the absence of cyclin-dependent kinase 4 and 6 inhibition for this patient population.To assess whether fulvestrant is superior to letrozole when combined with palbociclib in the first-line scenario.In this international, randomized, open-label, phase 2 clinical study conducted from July 30, 2015, to January 8, 2018, patients with hormone receptor-positive, ERBB2-negative advanced breast cancer with no prior therapy in the metastatic setting and endocrine-sensitive criteria were recruited from 47 centers in 7 countries. Data were analyzed from February 11 to May 15, 2020.Patients were randomly assigned (1:1 ratio) to receive palbociclib with either fulvestrant or letrozole. Stratification factors were type of disease presentation (de novo vs recurrent) and the presence of visceral involvement (yes vs no).The primary end point was investigator-assessed progression-free survival determined by Response Evaluation Criteria in Solid Tumors, version 1.1.A total of 486 women (median age, 63 years [range, 25-90 years]; 3 Asian women [0.6%]; 4 Black women [0.8%]; 461 White women [94.9%]; 18 women of unknown race [3.7%]) were randomized (243 to fulvestrant-palbociclib and 243 to letrozole-palbociclib). Median investigator-assessed progression-free survival was 27.9 months (95% CI, 24.2-33.1 months) in the fulvestrant-palbociclib group vs 32.8 months (95% CI, 25.8-35.9 months) in the letrozole-palbociclib group (hazard ratio, 1.13; 95% CI, 0.89-1.45; P = .32). This result was consistent across the stratification factors. No significant differences were observed in objective response rate (46.5% vs 50.2%) and 3-year overall survival rate (79.4% vs 77.1%) for fulvestrant-palbociclib and letrozole-palbociclib, respectively. Grade 3-4 adverse events were comparable among treatment groups, and no new safety signals were identified. No treatment-related deaths were reported.Although fulvestrant-palbociclib demonstrated significant antitumor activity, this randomized clinical trial failed to identify an improvement in progression-free survival with this regimen over letrozole-palbociclib in patients with endocrine-sensitive, hormone receptor-positive, ERBB2-negative advanced breast cancer.ClinicalTrials.gov Identifier: NCT02491983.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
冬瓜完成签到 ,获得积分10
1秒前
Fu发布了新的文献求助10
1秒前
tuanheqi应助旷野天采纳,获得30
2秒前
2秒前
材料诚完成签到,获得积分10
2秒前
LabRat完成签到 ,获得积分10
2秒前
caibai发布了新的文献求助10
3秒前
幽默不乐完成签到,获得积分20
3秒前
Bzz完成签到,获得积分10
4秒前
5秒前
研友_VZG7GZ应助乐白采纳,获得10
5秒前
oldfive发布了新的文献求助10
5秒前
6秒前
在水一方应助月秋采纳,获得10
6秒前
小鸟芄完成签到,获得积分10
6秒前
Michael发布了新的文献求助10
7秒前
阔达的扬完成签到,获得积分10
7秒前
琪琪的发布了新的文献求助10
8秒前
HanQing完成签到,获得积分20
8秒前
10秒前
11秒前
丘比特应助不过尔尔采纳,获得10
12秒前
自觉秋发布了新的文献求助10
12秒前
小贺完成签到,获得积分10
14秒前
学术小白发布了新的文献求助10
14秒前
N7完成签到,获得积分10
14秒前
qgjvjypm发布了新的文献求助10
14秒前
15秒前
搜集达人应助枯木逢春采纳,获得10
15秒前
Michael完成签到,获得积分20
16秒前
四川知名猛男完成签到 ,获得积分10
16秒前
可爱的函函应助科研通管家采纳,获得100
16秒前
科研通AI2S应助科研通管家采纳,获得10
16秒前
iNk应助科研通管家采纳,获得10
16秒前
17秒前
打打应助科研通管家采纳,获得10
17秒前
17秒前
科研通AI2S应助科研通管家采纳,获得10
17秒前
高分求助中
Sustainability in Tides Chemistry 2000
Microlepidoptera Palaearctica, Volumes 1 and 3 - 13 (12-Volume Set) [German] 1122
Дружба 友好报 (1957-1958) 1000
The Data Economy: Tools and Applications 1000
Mantiden - Faszinierende Lauerjäger – Buch gebraucht kaufen 700
PraxisRatgeber Mantiden., faszinierende Lauerjäger. – Buch gebraucht kaufe 700
A Dissection Guide & Atlas to the Rabbit 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3101389
求助须知:如何正确求助?哪些是违规求助? 2752795
关于积分的说明 7621022
捐赠科研通 2405111
什么是DOI,文献DOI怎么找? 1276127
科研通“疑难数据库(出版商)”最低求助积分说明 616705
版权声明 599058